Home · Health · Sep 27 archive
Orforglipron Shows Weight Loss Benefits Across Menopausal Stages
Developing
In Short: A new study published in Medscape highlights the effectiveness of orforglipron, an oral non-peptide GLP-1 receptor agonist, in managing obesity among women across different menopausal stages.
Among women with obesity, or those who are overweight with at least one obesity-related complication, orforglipron led to greater reductions in body weight and waist circumference compared to a placebo.
The research, supported by Eli Lilly and Company, the manufacturer of orforglipron, underscores the drug's potential as a tool for weight management in diverse populations.
Lead author of the study commented, 'These findings underscore OFG's [orforglipron] efficacy in managing obesity across different menopausal stages,' emphasizing the drug's broad applicability.
While the study provides promising results, it does not address long-term effects or potential side effects of orforglipron, which will require further investigation.
What this adds
The study adds to the understanding of orforglipron's efficacy in managing obesity, particularly in women of varying menopausal stages, but does not provide information on long-term outcomes or side effects.
Background
Brazil's President Lula announced a 15% increase in welfare payments and free weight-loss jabs, drawing criticism from opponents who see it as an electoral ploy.
What's still developing
- Nothing material beyond the confirmed record.